RedHill Biopharma (RDHL) Common Equity (2016 - 2024)
Historic Common Equity for RedHill Biopharma (RDHL) over the last 15 years, with Q2 2025 value amounting to -$4.4 million.
- RedHill Biopharma's Common Equity fell 733278.69% to -$4.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.4 million, marking a year-over-year decrease of 733278.69%. This contributed to the annual value of -$4.7 million for FY2024, which is 32634.12% down from last year.
- Latest data reveals that RedHill Biopharma reported Common Equity of -$4.4 million as of Q2 2025, which was down 733278.69% from -$4.7 million recorded in Q4 2024.
- RedHill Biopharma's Common Equity's 5-year high stood at $53.0 million during Q1 2021, with a 5-year trough of -$48.4 million in Q4 2022.
- Over the past 5 years, RedHill Biopharma's median Common Equity value was -$2.2 million (recorded in 2024), while the average stood at -$1.3 million.
- Its Common Equity has fluctuated over the past 5 years, first soared by 10427.48% in 2023, then crashed by 733278.69% in 2025.
- RedHill Biopharma's Common Equity (Quarter) stood at $8.9 million in 2021, then plummeted by 645.35% to -$48.4 million in 2022, then soared by 104.27% to $2.1 million in 2023, then plummeted by 326.34% to -$4.7 million in 2024, then increased by 5.79% to -$4.4 million in 2025.
- Its last three reported values are -$4.4 million in Q2 2025, -$4.7 million for Q4 2024, and $61000.0 during Q2 2024.